





Plan de Recuperación, Transformación y Resiliencia



Financiado por la Unión Europea NextGenerationEU





Annual Report



Digital version number: 15624028X D.L.: M-8641-2024

Published by Ministry of Science, Innovation and Universities



Design and layout



Copyright / license of use

Attribution-Noncommercial use. Share alike by-nc-sa.

No commercial use of the original work or any derivative works is permitted. Distribution of derivative works must be made under a license equal to that which governs the original work.

General catalog of official publications

Publication included in the editorial program of the Ministry of Science, Innovation and Universities





To all the staff of the centers, areas, and units of the ISCIII for their effort and active participation in the writing of this document.

Index

1. Presentation

2. ISCIII 2023 in

3. Strategic Proj

EWRP for Cut

Addendum to

ISCIII in the PE

4. ISCIII during European Uni

5. 2023 Highlights

	80
n figures	16
ject: PERTE for Cutting-Edge Health	22
tting-Edge Health	24
the ETPF for Cutting-Edge Health	25
ERTE for Cutting-Edge Health	28
the Spanish Presidency of the ion Council	32
hts	36

Presentation



Presentation

he presentation of ISCIII's report on activities in 2023 has a very special framework that sets it apart from all the previous ones, because on July 5th, 2023 the Council of Ministers approved an agreement declaring the end of the health crisis caused by the COVID-19 disease, thus closing a period of several years that had been complicated for many people and of transformations in our organisation. I have always said that the bitter consequence of the pandemic has been that science in general, and that developed through the national health system in particular, has been at the centre of many of the different solutions that allowed the World Health Organisation to declare the end of the international health emergency. An example of this is that, after the pandemic, the ISCIII is one of the 20 organisations in the world with the greatest scientific impact on health.

This is the result of three elements that appear in this report: firstly, the people, around 3000 women and men, who, through different forms of association with the ISCIII and its centres, have done what they do the best: science to protect people's health; secondly, the budgetary commitment, having enjoyed the largest sustained budget in our history during these years; and thirdly, the complicity with patients and families who have helped us with their perspective and collaboration to make a better choice of what we do.

In the following pages you will see how the ISCIII has continued to cultivate science, both our own through our affiliated research centres, and that of others, as we maintain a growing intensity of funding for research carried out within the scope of the National Health System and centres dedicated to biomedicine. Specifically, this year we have allocated almost 300 million euros to research projects, clinical trials, and contracts for hundreds of researchers.

We will also show you the different mechanisms by which we have supported the National Health System by providing numerous high-value scientific and technical services, including the doping control laboratory, following its successful integration in 2022.

However, understanding that those who read this document will wish to delve deeper into those aspects that are of greatest interest to them, I would like to highlight some of the differential aspects that they will find in reading this report.

The Spanish Presidency of the Council of the EU and the internationalisation of our activity as a driving force for Science in Health.

In the second half of this year, Spain has successfully held the Presidency of the EU Council. The ISCIII has played a central role in ensuring that, as part of this event, Spain has shown its consolidation as a benchmark in the European research area, especially in the field of health and biomedicine.

In this regard, the Institute has been directly involved in various high-level meetings, conferences, and health events and, above all, in supporting the Ministry of Science, Innovation and Universities and the Ministry of Health. We are particularly proud of the events held in Valencia and Madrid on personalised precision medicine, which brought together some of the most relevant scientists in this field, and the meeting of the European bioethics' committees. The actions of recent years, as well as the promotion of scientific policy in the field of health, make our Institute an emerging value in Europe, beyond the positions in the international rankings to which I referred earlier. We would like to highlight the visit paid to us by the European Commissioner for Health and Food Safety, which meant the recognition of our work.

Thus, our alignment with the European Research Area and being part of the international arena of science has been one of our priorities. This year we have continued to promote our internationalisation in the Horizon Europe framework programme. Among many other issues, we have coordinated the European ERA4Health Partnership, which promotes transnational collaborative research to



guarantee the coverage of public health needs, and we have participated very intensively in the Personalised Medicine Partnership, which had its opening ceremony during the Spanish Presidency of this semester.

In addition, we are present in numerous European research infrastructures, and this year we are firmly committed to the internationalisation of research in primary care in various initiatives that are already beginning to consolidate successfully.

We have continued in our intention to improve the opportunities that the Spanish health-oriented science system can offer its researchers

Funding for NHS research activity: flexibility and sustained funding.

This year, 2023, we have continued in our intention to improve the opportunities that the Spanish health-oriented science system can offer its researchers. To this end, we have reduced administrative burdens, optimised evaluation processes, promoted mobility, and added new lines of research in accordance with the needs of the public. Our objective, shared by the Ministry of Science, Innovation and Universities, is to make Spain an attractive country for science. Many of these actions have been deployed in 2023 and are already reflected in the AES 2024.

Thus, the combined budgetary efforts of the ISCIII with the help of funds from the PRTR, all under the coordination of the PERTE for Cutting-edge Health, has allowed us to achieve an execution in 2023 that exceeds 95% in the calls for research aimed at the scientific system in the field of health. The CERTERA call, aimed at selecting the entities that will form part of this consortium, deserves special attention due to the nature of its significance for people, both healthy and ill. We have invested 45 million euros which, together with the contributions of the selected entities and the ISCIII's own facilities for this purpose, will be allocated to a network infrastructure that allows us to take advantage of and coordinate the different capacities in the production of advanced therapy drugs in Spain. This infrastructure is aimed at ensuring that the drug prototypes that emerge from academic environments can reach early clinical trials as quickly as possible.

We have also strengthened public-private collaboration through the Transmissions' call. This call, launched in 2022, has been consolidated in our planning by transferring its funding from the PRTR to the ISCIII's own budgets. This year it has incorporated proposals of enormous value that have even allowed us to initiate, for the first time, a formal development collaboration between public hospitals and multinationals with high innovative power. Finally, we are grateful for the development of the FORTALECE programme by the MCIU in choosing our system of accreditation of Institutes as a basis for exploring the effectiveness of structural and flexible funding for centres of excellence. This programme pursues the transformation of the centres through the innovative effect, the gender perspective, and the search for excellence, among other parameters. Its extension to the rest of the science system is the key to continuing the commitment to science as a transformative element.

Intramural research and scientifictechnical services: our own and affiliated centres.

Another of our hallmarks is our own research. Through the researchers at our centres and units, this year we have carried out cutting-edge studies in numerous fields. On the one hand, the state foundations attached to the ISCIII, such as the CNIO, CNIC and CIEN, have continued to lead scientific production of the highest international excellence in their respective fields of knowledge. Nowadays, no one understands research in cancer or cardiovascular diseases

worldwide without reference to these centres, where some of the most renowned people in the scientific world work. Their relevance is the product of a delicate combination of excellence and tenacity, employing hundreds of researchers under the umbrella of the ISCIII, which provides several tens of millions of euros a year to support them. Furthermore, our CIBER consortium continues at a level of scientific production of the highest level, providing a response to the public by employing around 1000 scientists in more than 50 centres distributed throughout Spain. The integration of the areas of knowledge of infectious and neurodegenerative diseases has reached cruising speed during this year 2023. In addition, the first joint strategic plan has been approved after the successful completion of the merger of all its areas of knowledge into a single legal entity.

Through the researchers at our centres and units, this year we have carried out cutting-edge studies in numerous fields

On the other hand, our public health research centres, still under pressure from the pandemic, have continued to play a central role. This year, continuing with the scientific contributions of the ISCIII in relation to the pandemic associated with the SARS-CoV-2 virus, we have maintained our collaboration with Hipra. Our contributions, let me say with pride, have been key to obtaining definitive approval, both for its use and for subsequent modifications, which allow it to be adapted to the vaccination strategy established by the health authorities. This contribution of the ISCIII must be understood in combination, among other actions, with two of the great scientific contributions of our organisation to the pandemic: the ENE Covid and CombiVacs studies. From my perspective, these three elements, together with the designs of the new epidemiological and microbiological surveillance systems, are the keys to the practical and applied contribution of Spanish science to the SARS-CoV-2 pandemic. Applied science to protect the health of real people. I invite you to review the summary document we published a few months ago on our role in the management of the SARS-CoV-2 pandemic to get an idea of our contributions. In this regard,

our surveillance of respiratory viruses, such as influenza, SARS-CoV-2, and RSV, continues to provide critical data for public health and population protection.

But this year, our public health research activity has had successes that go beyond Covid. Just to highlight a few examples, we have established a map of the prevalence of obesity in Spain, and we have identified how excess weight affects adults, children, and adolescents. This map, where socio-economic determinants play a key role, will allow us to provide scientific evidence for the policies designed for this purpose. We have also continued to do science on climate change and the influence of environmental pollutants on our health by applying, among other strategies, advanced human biomonitoring techniques. This is providing us with valuable information on the exposure of the population to chemical substances and their potential health risks.

We have also continued to develop organoids, which are mini organs developed in the laboratory that mimic the function of real organs, in conjunction with the different research support platforms that provide services to the different research groups throughout the country, and which allow us to improve research into various diseases. Our commitment to alternative disease models for experimental use is also very strong.

We have completed the construction of the Centre for Advanced Therapies, which has been configured as a transversal department for the entire organisation. Its role and its alliances with CERTERA will be reflected throughout 2024 in the advanced therapy drug development strategy reflected in the PERTE for Vanguard Health.

I would also like to remind you that we have a great novelty in the Institute: the incorporation of the Madrid Doping Control Laboratory. Throughout 2023, the laboratory has reinforced its work, providing services in the fight against malpractice in sport. For example, we have just signed an agreement with UEFA for the laboratory to carry out tests on footballers participating in its various competitions.

The people

Finally, I will focus my last words on the people who, directly or indirectly, make up the ISCIII. On the one hand, our workers, our real strength. Without their commitment and dedication, it would be impossible to build this common home that is the ISCIII. I would like to thank you for your work from each of your positions, scientific and non-

scientific, maintaining the facilities or guaranteeing our security from the sentry boxes, laboratory technicians or occupational risk prevention technicians, IT staff and even people linked to external suppliers who have shared many hours with us throughout this year, our colleagues in the cafeterias and those who have retired over the last few years, despite the fact that we have tried to retain your talent. On the other hand, it is only fair to acknowledge the work of my colleagues at FIS, who have managed to manage and resolve a tremendous number of grants, guaranteeing the defence of applicants and their rights. I would also like to thank the more than one thousand scientific evaluators external to the ISCIII, who have helped us to conclude all this year's calls for proposals with excellence and rigour, distributing several hundred million euros to the science system associated with the NHS with scientific fairness. And, of course, to patients and their families, the true destination and path of our research activity. We began a journey together in 2020 and throughout 2023 it has been consolidated with different agreements in which citizen participation goes beyond collaboration in the evaluation of research projects: now, in addition, we do science together.

Cristóbal Belda

Custibel Belda

s the current director of the Carlos III Health Institute, it is an honor to resume the work that so many people have carried out before me, since the institute was created in 1986. Following the path opened by all the people who preceded us, my objective is none other than to continue consolidating the work of the ISCIII as a bridge between science and health.

I have come to this position after more than 30 years working in this house, so being the head of the ISCIII is an honor, a responsibility and a commitment to which I will dedicate all my efforts.

As Dr. Belda explains, in 2023 we have finally seen the end of the COVID-19 pandemic, a crisis on which the Institute has not stopped working in the last 4 years, and which still occupies part of our research, because the virus persists and we must never stop studying this and other possible threats to public health. The pandemic has allowed us to demonstrate once again the value of the ISCIII and its contribution to the Spanish Science, Technology and Innovation System (SSTIS) and the National Health System (NHS), making our goal of collaborating with scientific knowledge to protect and improve the health of the Spanish population.

The year 2023 has been an important and productive one for the Institute and consolidates a path that we will continue to open up and follow in the coming years. The year that occupies this report has left impulses and advances in scientific fields very relevant to the Institute, such as, among many others, microbiological and epidemiological surveillance, rare diseases, precision medicine, health care, environmental health, digital health, advanced therapies, tropical medicine, cancer, cardiovascular diseases, neurodegeneration... Moreover, 2023 has allowed us to incorporate a new area of study: doping control. As always, we have continued to promote, and will continue to do so, the funding of science, through the Strategic Action in Health (AES), the main tool for funding health research in Spain. 2023 has also been an important year for internationalization and for our participation in the European Research Area, an area that we will continue to promote with total commitment, because science is global.

Finally, I would like to dedicate a few words to all the people who work at the Institute. Thanks to them we continue growing and doing our bit in this task, shared with the entire National Health System, of improving people's health through knowledge. I am fully committed to ensuring that our Institute continues to successfully carry the flag for health research in Spain.

Marina Pollán






ISCIII 2023 in figures



ISCIII 2023 in figures

ISCIII staff





Budget

€ 487,532,150

R&D&I Financing and coordination in the National Health System (NHS):

€ 264,811,012 financing

Funded by the Recovery, Transformation and Resilience Plan (PRTR):

29%

men

€ 159,117,050

1.295 awarded grants

FSE Funds

certified grants

€ 18.1 m

in declared expenditure

401



Publications by centres and units

471 indexed publications in 2023

4,521.1 cumulative impact factor points Total AES-2023 funding in R&D&I programmes and sub-programmes coordination

TALENT DEVELOPING, ATTRACTING AND **RETAINING STATE PROGRAMME**

495 awarded grants financing

State Training Sub-programme*: 273 grants awarded / € 23.441.780 State Integration Sub-programme: 140 grants awarded / € 21.729.300

STATE PROGRAMME FOR THE PROMOTION OF SCIENTIFIC-TECHNICAL RESEARCH AND ITS TRANSFER

752 awarded grants

€ 209,896,854.05 financing

State Knowledge Generation Sub-Programme: 522 awarded grants / € 76,839,841.25 State Knowledge Transfer Sub-Programme: 218 awarded grants / € 103.119.908.66 State Institutional Strengthening Sub-programme: 12 awarded grants / € 29,937,104.15

STATE PROGRAMME TO ADDRESS **ENVIRONMENTAL PRIORITIES**

48 awarded grants € 8,402,638 financing

State Internationalisation Sub-programme: 48 awarded grants / € 8,402,638.57

Intramural Scientific Activity at the ISCIII

€ 46,511,520

State Mobility Sub-programme: 82 grants awarded / € 1.340.440

projects awarded with a total funding of

84

€ 8,228,678

international projects with funding of € 868,971

297 current projects with a total funding of

€ 38,946,533



Annual Report 2023 0

Training Activities

Virtual Campus for Health Professionals:

12,526 students

in 24 training actions

National Health School:

864 students

in training and 3,738 teaching hours.

National Occupational Medicine School:

966 students

in training and 1,526 teaching hours.

Scientific-Technical Support Services to the National Health System

27

Microbiological Surveillance

programmes (bacteria,

parasites, viruses, and fungi)

80

actions in the genetic diagnosis

of Retinoblastoma, Alpha-1

antitrypsin deficiency and

Epidermolysis Bullosa

213

outbreaks characterisation

(Botulism, Salmonellosis,

Legionellosis, Viral

Gastroenteritis.

Cryptosporidium and Marburg)

712 Covid-19 diagnostics and sequencing of 1 SARS-CoV-2 variant

32.148

diagnostic and/or reference determinations of the **CNM's Service Portfolio**


2.989

in-competition and 1.857 out-of-competition services provided by the Doping Control Laboratory

143.822

tests and preparation of reports and export certifications on air quality, radiation protection and environmental toxicology

Cutting Edge Health PERTE





€ 2,695 m Investment € 2,208.89 m € 486.88 m are public investment are private funding The ISCIII represents 22% of the total public contribution to the PERTE for Vanquard Health. Actions Joint ISCIII-CDTI call for innovation linked to Personalised Medicine and Advanced Therapies for a total value of € 15,84 m and 20 research groups ISCIII platforms to support research (biobanks-bio models, ITEMAS, SCReN) € 30 m Participation of the ISCIII during The Spanish Presidency of the Council of the European Union Conference on Personalised Medicine: The Evolution of

- Healthcare to Improve People's Lives
 - IMPaCT Precision Medicine Infrastructure
 - EU Cancer Mission
- High level meeting on Cancer organised by the Ministry of Health with a presentation on Mission Cancer
- High level meeting on Childhood Obesity with a presentation on integrated health care for childhood obesity.



National Health

Sciences Library

104,417 database queries

+127 m

visits to SciELO Spain (Spanish health science iournals in open access)

Comunication



87 press releases sent to the media

132 ormative news published on the website and 6 outreach news releases

32 deos published and 14 events broadcast live



+ 5,4% growth over 2022. 3.7 million impressions



More than 630.000 impressions



Strategic Project: PERTE for Cutting-Edge Health



PERTE for Cutting-Edge Health

The Economic Recovery and Transformation (PERTE) for Cutting-Edge Health Strategic Project is conceived as a country proposal of general interest for society, boosting quality employment and improving the health of the Spanish population through scientific knowledge, cutting-edge health innovation and data as vectors of transformation and for the Spanish economy due to its capacity for dragging and transforming potential. It should act as a **backbone and driving force** to consolidate the protection of collective and individual health against any threat, regardless of its scale, as one of the elements of social and economic recovery.

The general objective of

PERTE focuses on improving the

The Cutting-edge Health Perte started with a publicprivate investment of 1,469.32 million euros to be executed during the period 2021-2023. The public contribution amounted to 982.44 million euros, while the private contribution was 486.88 million euros. However, since its launch in November 2021, the PERTE for Cutting-Edge Health has been growing gualitatively and guantitatively. Its initial budget has been increased in this period with 388.38 million euros of additional funds for certain actions already established and funding linked to new actions.

News link:



prevention, diagnosis, treatment, and rehabilitation of patients in our National Health System, as well as protecting the health of citizens through precision medicine, advanced therapies, and artificial intelligence, strengthening the Carlos III. industrial sector and the creation of quality employment.

For administrative coordination, the PERTE has a **Governance** through an Interministerial Working Group, co-chaired by the heads of the Ministry of Science, Innovation and Universities and the Ministry of Health and participated by representatives of all the ministerial departments involved in the PERTE and representatives of the General Secretariat for Economic Affairs and G20. It also has a Technical Office located at the Instituto de Salud

The PERTE governance must reflect public-private collaboration, and to this end, the Alianza Salud de Vanguardia (Cutting-edge Health Alliance) was created, which integrates the Interministerial Working Group, representatives of the Autonomous Communities, representatives of the private sector and representatives of citizens and patients.

From December 2023, PERTE enters a new phase with the appointment of Dr Raguel Yotti as PERTE Commissioner for Cutting-edge Health. This Commissioner will be dedicated to coordinating follow-up, interlocution and visibilisation measures in collaboration with the ministerial bodies involved in PERTE, and with the rest of the bodies and actors involved.

News link:



Cutting-Edge Health PERTE Addendum

The approval in October 2023 of the Spanish Addendum, by the European Commission, has meant a reinforcement of 830 million euros for the PERTE for Vanguard Health which, managed by the Ministry of Health and the Ministry of Science, Innovation and Universities, will be allocated to new actions among which stand out: the extension of the Customized Digital Care Plan, the implementation of the Genomic Services Portfolio in the National Health System and research in Precision Medicine, the improvement of healthcare for patients with rare diseases such as ALS and the increase in research funding in this field, the reinforcement and internationalisation of the sector's industrial capacities and the financing of Spanish companies in the field of health.

Therefore, the Cutting-Edge Health PERTE has ended in 2023 with a total investment of 2,695 million euros, of which 2,208.89 million euros are public investment, while 486.88 million euros are private funding.



The Cutting-Edge Health **PERTE**

€ 2,208.89 m public sector contribution

€ 486.88 m private contribution Annual Report 2023 25 /



The Cutting-Edge Health PERTE is structured **around four strategic objectives** and **five strategic implementation lines** that ensure the achievement of these objectives and are identified as critical elements of success.

OE1 **OE2** OE3 **OE4** Digital transformation Personalized Precision Advanced Therapies Innovative data system for NHS Medicine of healthcare and other Innovative Therapies **LT1** Strengthen and develop the capabilities of the NHS LT2 Develop and modernize innovation-oriented industrial capacity **LT3** Collaboration and coordination between scientific and industrial sectors LT4 Territorial cohesion LT5 Training

It is worth highlighting the participation of ISCIII in the new actions included in the Addendum, as it will develop 7 new actions with a total budget of 122 million euros, which means that ISCIII's contribution to the Cutting-Edge Health PERTE is more than 400 million euros, 21% of the total public investment in the Cutting-Edge Health PERTE.

OE/LT	ACTION	m€
OE1	Joint Missions of the Ministry of Science and Innovation and the Ministry of Health for Rare Diseases	20
	Joint missions of the Ministry of Science and Innovation and the Ministry of Health for implementing precision medicine - Genomics	25
LTI	Actions related to the development and strengthening of SNS capacities for clinical research - Clinical Research Units	45
	Proteomics and metabolomics platform	2,4
	Human Biomonitoring Infrastructure	1
	Module for the generation of poly-transgenic animals for xenotransplantation research	1,6
LT2	Financial aid in the form of loans to NHS research centres to expand their research and technological development capacities	27

These new actions will improve the coverage and attention to the health needs of the population. The new economic resources with which the Cutting Edge Health PERTE is reinforced, will allow to boost investments aimed both at incorporating new technologies and equipment, including interoperable and homogeneous information systems, and at reinforcing the research and technological development capacities of the NHS, strengthening the Spanish R&D&I ecosystem at a public and private level.

ISCIII participation in the cutting-edge health PERTE

From the beginning of the Cutting Edge Health PERTE in November 2021 until 2023, ISCIII has managed a total of 19 actions with a budget of 319.54 million euros, mainly from the European Funds of the Recovery, Transformation and Resilience Plan, but also from its own funds from the General State Budget. Thus, ISCIII represents 22% of the total public contribution to the Cutting Edge Health PERTE.

€ 319.54 m	OE1: Personalized Precision Medicine	€ 111 m
22% Public contribution € 296.95 m	OE2: Advanced Therapies and other Innovative Therapies	€ 170 m
93% executed	LT1: Strengthen and develop the capabilities of the NHS LT5: Training	€ 16 m

OE2: Advanced Therapies and other Innovative Medicines

Call for Independent Clinical Research (ICI)

€ 14.78 m for 22 research groups

€ 15.84 m (€ 9.27 m contributed by the ISCIII) for 20 research groups

Creation of a Advanced Therapies Consortium (C-TA) for a total value of

€ 67.50 m where the following amounts have been implemented in 2023:

→€ 5.58 m

in two tenders already awarded for the construction of the high security laboratory in the C-TA at the Majadahonda Campus (Madrid) and part of equipment.

The total execution of this action is € 56.48 million¹.

ISCIII R&D and transfer support platforms

(ITEMAS, SCReN) to foster innovation capacities in health technologies and the implementation of Precision Medicine continue their contribution to the Cutting Edge Health PERTE through the 2023 call for a total value of

€ 30 m for the three platforms:

- \rightarrow Biomodels and Biobanks

¹It also includes the AES 2021 RICORS call of the Advanced Therapies Network - TERAV.



Joint Call ISCIII-CDTI for innovation linked to Personalised Medicine and Advanced Therapies - "Transmissions" for a total value of



→€ 45 m

contributed additionally from the MRR, for the call for incorporation of research entities to the consortium of advanced therapies. The objective of the **CERTERA Consortium** is to facilitate preclinical development and to articulate the nodes of a research network on advanced therapy drugs in which research centres and hospitals of the Spanish National Health System will participate. This consortium will have its own legal personality and network structure. The call for proposals finally awarded the € 45 million to 43 centres.



→ Dynamization and Innovation of the NHS industrial capacities and their effective transfer to the productive sector \rightarrow Support for Clinical Research

Annual Report 2023 29

LT3: Collaboration and Coordination between the scientific and industrial sectors

- → ISCIII Clinical Research platform (SCReN*)
- → Platform for the dynamization and innovation of the NHS industrial capacities and their effective transfer to the productive sector ISCIII- ITEMAS*².

Two actions are pursued within the framework of this platform:

- \rightarrow Health Innovation Projects portfolio
- \rightarrow Monitoring system for projects in pre-clinical phases

LT5: Strengthen and articulate new training programmes between companies, the NHS and R&D&i centres

→ ISCIII Grants for Training in Health Research Management, worth € 126,000 for two graduates.

Information on Cutting Edge Health PERTE in:



²Both platforms come together in two transversal lines LT1 and LT3

Related news:











ISCIII during the Spanish Presidency of the European Union Council

U23

we are researching new strategies to achieve opersonalise approach to **prevention**, **diagrosis** and **treatiment**

Personalised measure require shared infrastructures and data platforms

The evolution of healthcare to improve people's lives

Internation Cooreration

is key for the devel pment perso ialised medic ne



ISCIII during the **Spanish Presidency** of the European **Union Council**

The Instituto de Salud Carlos III (ISCIII) has organised and participated in several events within the framework of the Spanish Presidency of the Council of the EU.

On the one hand, it organised two scientific events in Valencia, one on the IMPaCT Precision Medicine Infrastructure and the other on the EU Cancer Mission - together with the Centre for Technological Development and Innovation (CDTI) - prior to the Conference on Personalized Medicine: The evolution of health care to improve people's lives.

The conference was organised by the Ministry of Science and Innovation and the ISCIII itself, with the support of Fundación Española para la Ciencia y la Tecnología (FECYT). These meetings were attended at the highest level by representatives of the national and international scientific and health community.

The conference dedicated to the **IMPaCT Infrastructure** was opened by the Deputy Director of International Research Programmes and Institutional Relations of the ISCIII, Daniel Ruiz Iruela, and included two scientific sessions: 'Precision Medicine in Europe and the development of Genoma Europa: situation and lines of development', and 'IMPaCT: Spain's strategy for the development of **Precision Medicine**'. Among others, representatives from the ISCIII, the Barcelona Supercomputing Center (BSC-CNS), several Health Research Institutes (IIS), the Platform of Patient Organisations (POP), the European Genomic Data Infrastructure (GDI), the 1+ Million Genomes Initiative (1+ MG) and the Institute of Human Genetics participated.

Throughout the two sessions, messages such as the benefits of cooperation, the relevance of training, the importance of data science, the promotion of debate on bioethical issues and the challenge of ensuring patient participation, among others, were highlighted.

The second of the satellite events to the Precision Medicine Conference on Tuesday was dedicated to the Cancer Mission and was attended by the ISCIII, represented by Dr. Rosario Perona Abellón, and the Centro para el Desarrollo Tecnológico Industrial (CDTI), represented by Marta Gómez Quintanilla, as coordinators of the Spanish Mirror Group in the Mission. Representatives from the European Commission's Directorate-General for Research and Innovation, the European Society for Medical Oncology (ESMO), the Spanish Association Against Cancer, the Spanish Association of Bio companies (ASEBIO) and the Spanish pharmaceutical laboratory employers' association (Farmaindustria), among others, also took part. The session will also analyse the possible synergies of the Cancer Mission with the other four European Missions: Climate Change, Smart Cities, Water and Oceans, and Soil and Food Health.

In addition, the Sub directorate General for Cell Therapy and Regenerative Medicine of the ISCIII and the Spanish Bioethics Committee (CBE), an independent body attached to the Ministry of Health and whose Secretariat is located at the ISCIII, co-organised the NEC: 32 Forum meeting, which is a meeting of all the National Ethics Committees of the different EU countries. The meeting took place at the Ministry of Health. Ernest Lluch Hall. Madrid November, 27th-28th 2023.



The Instituto de Salud Carlos III has also collaborated in:

 \rightarrow High-level meeting on Cancer organised by the Ministry of Health with a presentation on Mission Cancer Ministry of Health Palacio Real de Pedralbes Barcelona, August, 31st 2023.





→ High Level Meeting on Childhood Obesity with a presentation on comprehensive health care for Childhood Obesity organised by the Ministry of Health October,17th 2023. La Palma Conference Centre.





omentar la competitividad de ndustria biomédica española

OBJETIVOS TRANSVERSALES

0000

The second secon

St - Die Bai Barik

198

S.

9

36 / 2023 Highlights



K-

mst

2023 Highlights

January

01/09/2023

ISCIII-IARC Conversations. Fourth meeting: Epigenomics and mechanisms of cancer https://www.youtube.com/watch?v=31P5QQI65-w&t=1s

01/26/2023 María Jesús Perteguer, CNM-ISCIII, World Day 2023 on Neglected Tropical Diseases https://www.youtube.com/watch?v=D8GpkR80C70&t=47s

01/26/2024 World Day 2023 on Neglected Tropical Diseases https://www.youtube.com/watch?v=Qe6HSQwilG4&t=20s

February

02/06/2023 HBP EBRAINS New opportunities for neuroscience research https://www.youtube.com/watch?v=yz2PHuRU4SE&t=1732s

02/07/2023 2023 International Day for Women and Girls in Science at the ISCIII

https://www.youtube.com/watch?v=vV1LtsP6bJY&t=204s

02/09/2023 2023 International Day for Women and Girls in Science VI ISCIII Days https://www.youtube.com/watch?v=4w0yBvRd4-Q&t=2039s

02/09/2024

2023 International Day for Women and Girls in Science at the ISCIII https://www.youtube.com/watch?v=u2qeLrPJIpY

02/21/2023

Ana Cañas, director of the National Centre for Environmental Health of the ISCIII https://www.youtube.com/watch?v=gCqR8LNydgl&t=10s

02/27/2023

Ignacio Pérez de Castro, Instituto de Investigación de Enfermedades Raras (Rare Diseases Research Institute) Gene therapy and CRISPR https://www.youtube.com/watch?v=leSqQqodRIM&t=9s

March

03/08/2024 International Women's Day 2023 https://www.youtube.com/watch?v=-d7Hz2ukUR8&t=11s

03/14/2023 Cristóbal Belda. Director of the ISCIII. AES 2023 Summary and news https://www.youtube.com/watch?v=_g2Zsp5xXMM&t=15s

03/21/2023 Presentation of the 2023 ISCIII's Strategic Action in Health https://www.youtube.com/watch?v=2hnYLaX8ev8

03/24/2023 CINEFORUM ANTONIO INIESTA https://www.youtube.com/watch?v=V00geu63X4k

03/24/2023 2023 Open Government Week at the ISCIII: visits to the Chamartín and Majadahonda Campuses https://www.youtube.com/watch?v=pwRnLqjsYmU&t=10s

April

04/19/2023 One Health Outreach. Israel Cruz, ENS-ISCIII https://www.youtube.com/watch?v=1_lbsm45kQM&t=13s

04/19/2023

Francisco Javier García, head of the ISCIII OTC, explains its objective and functioning https://www.youtube.com/watch?v=OjurSzbfcts

May

05/18/2023 **CNE-SEE** Dav https://www.youtube.com/watch?v=KUunBtVnHmU

05/31/2023 Access to medicines as a global health issue https://www.youtube.com/watch?v=t82C75vaqkE

June

06/06/2023 International Women's Health Action Day https://www.youtube.com/watch?v=hkVW1eloQ8Q

06/22/2023 ISCIII-CDTI Call https://www.youtube.com/watch?v=AI7W8Gp8A-M

06/28/2023

Presentation of the 'The ISCIII and COVID-19: work during the pandemic' report https://www.youtube.com/watch?v=VwlK4nrph4g&t=1526s

July

07/04/2023 CONFERENCE: European Research Infrastructures in the Health Area https://www.youtube.com/watch?v=hM9WRdvFGSw

07/20/2023

FORTALECE (IIS) and PLATAFORMAS (R&D&I in Biomedicine and Health Sciences) Call https://www.voutube.com/watch?v=328KLKu83W8

August

08/03/2023

Asunción Díaz, CNE researcher, speaks about ITS https://www.youtube.com/watch?v=vgTbPnxMX7o&t=3s

08/24/2023 Microscopy in biomedical research. Diego Megías, ISCIII researcher https://www.youtube.com/watch?v=vYlhPrO_-mo

October

10/06/2023 ISCIII dissemination activity (CNSA) for the 2023 Researchers' Night https://www.youtube.com/watch?v=CUKOhABJ9t8

December

12/05/2023 Summary video 2023 Science Week at the ISCIII https://www.youtube.com/watch?v=Y9OYMjSa2J0

12/14/2023 FUNDING OPPORTUNITIES IN THE FIELD OF **BIOMEDICINE AND HEALTH IN 2024 HORIZON** EUROPE https://www.youtube.com/watch?v=d9M6iNnCjc4

12/31/2023 Summary video 2023 Science Week at the ISCIII. Cristóbal Belda https://www.youtube.com/watch?v=Ur2yWJhWom







